Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
Clin Transl Oncol ; 12(9): 629-33, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20851804

ABSTRACT

INTRODUCTION: Kaposi sarcoma (KS) is a mesenchymal tumor originating from lymphatic endothelial cells. Immunosuppressive patients have higher risk for KS. HHV-8 has a role in immunopathogenesis of KS. Aim Evaluation of demographical properties with tumor characteristics and treatment modalities of KS. MATERIAL AND METHOD: Histopathologically documented KS patients were evaluated retrospectively. Anti-HIV seroprevalence was also evaluated with patient and tumor characteristics besides treatment regimens. RESULTS: Fifty-one patients were included between September 1998 and February 2009. Male/female ratio was 3.25 (39/12). Median age was 68 (31-94). Lower extremity was the most common site whereas excisional biopsy was the most common diagnostic procedure. Smoking rate was 42.8%. Twenty percent had family history for cancer. Anti- HIV seropositivity rate was 1.9%. Thirty eight percent had local monotherapy, and radiotherapy was most common (26%). Multidisciplinary approach rate was 44%. Most of them had surgery and radiotherapy combination. Two-third of the patients had radiotherapy alone or with other modalities. Rates were as 12% for chemotherapy and 6% for interferon. Vincristine-bleomycin-doxorubicin combination was the most preferred regimen (60%). CONCLUSION: Male patients in the sixth decade seem to have higher risk for KS. Smoking rate was almost as high. Local therapy might be sufficient in most of the patients. However, we may also consider systemic chemotherapy for selected patients, including vincristine, bleomycin and doxorubicin.


Subject(s)
Sarcoma, Kaposi , Skin Neoplasms/diagnosis , Adult , Aged , Aged, 80 and over , Angiogenesis Inhibitors/therapeutic use , Antineoplastic Agents/therapeutic use , Antiviral Agents/therapeutic use , Combined Modality Therapy , Female , HIV Seropositivity , Herpesvirus 8, Human , Humans , Interferon-alpha/therapeutic use , Interleukin-12/therapeutic use , Male , Middle Aged , Recurrence , Retrospective Studies , Risk Factors , Sarcoma, Kaposi/diagnosis , Sarcoma, Kaposi/therapy , Sarcoma, Kaposi/virology , Skin Neoplasms/drug therapy , Skin Neoplasms/radiotherapy , Skin Neoplasms/surgery , Skin Neoplasms/virology
SELECTION OF CITATIONS
SEARCH DETAIL